MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
8.31
+0.81
+10.73%
After Hours: 8.30 -0.01 -0.12% 19:59 01/14 EST
OPEN
7.52
PREV CLOSE
7.51
HIGH
8.45
LOW
7.52
VOLUME
11.28M
TURNOVER
--
52 WEEK HIGH
8.45
52 WEEK LOW
1.010
MARKET CAP
2.36B
P/E (TTM)
-18.4421
1D
5D
1M
3M
1Y
5Y
1D
Erasca Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Erasca Price Target Raised to $11.00/Share From $6.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $11
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Erasca (ERAS) and Connect Biopharma Holdings (CNTB)
TipRanks · 1d ago
Erasca (ERAS) Gets a Sell from Bank of America Securities
TipRanks · 1d ago
ERASCA, INC. <ERAS.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $11 FROM $6
Reuters · 1d ago
Erasca price target raised to $11 from $3 at Clear Street
TipRanks · 2d ago
Erasca announces ‘promising’ early clinical data for ERAS-0015
TipRanks · 2d ago
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.